ARVN — ARVINAS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1655759 ·
Last close
$7.51
Market Cap
$484.55M
52W High
$14.51
52W Low
$6.97
ADV30
804,121
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 249,700,000 | — | 164,100,000 | 169,400,000 | 675,100,000 | 94,300,000 | 113,000,000 |
| Mar 2026 | 15,600,000 | — | -63,800,000 | -57,600,000 | 647,500,000 | 87,300,000 | 260,700,000 |
| Dec 2025 | 9,500,000 | — | -74,600,000 | -67,400,000 | 717,900,000 | 142,900,000 | 284,100,000 |
| Sep 2025 | 41,900,000 | — | -43,800,000 | -35,100,000 | 844,300,000 | 101,500,000 | 279,900,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-207,000,000
Investing CF
$277,900,000
Financing CF
$-91,500,000
CapEx
$-1,800,000
Dividends Paid
—
Buybacks
$-74,100,000
EPS Diluted TTM
$0.10
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,500,600,000
Inventory
—
Receivables
$54,300,000
ST Investments
$473,600,000
EBIT TTM
$-18,100,000
Pretax Income TTM
$10,100,000
Interest Exp TTM
—
Analysts
14
Yahoo Snapshot (yfinance, live)
Total Revenue
$316,700,000
EBITDA
$-9,900,000
Free Cash Flow
$-94,500,000
Enterprise Value
$-7,386,686
Total Cash
$567,900,032
Total Debt
$8,000,000
Shares Out
64,521,198
Trailing EPS
$0.26
Book Value
$8.61
ROE
1.6%
ROA
-1.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 262,600,000 | -118,500,000 | -80,800,000 | 717,900,000 | 284,100,000 | 433,800,000 | -273,800,000 |
| Dec 2024 | 263,400,000 | -250,200,000 | -198,900,000 | 1,091,400,000 | 529,800,000 | 561,600,000 | -259,300,000 |
| Dec 2023 | 78,500,000 | -401,500,000 | -367,300,000 | 1,304,600,000 | 644,600,000 | 660,000,000 | -347,800,000 |
| Dec 2022 | 131,400,000 | -263,200,000 | -282,500,000 | 1,268,800,000 | 703,900,000 | 564,900,000 | -273,500,000 |
TTM Snapshot
Revenues TTM
$89,400,000
NetIncome TTM
$-221,300,000
OpCashFlow TTM
—
Assets (Latest)
$647,500,000
Forward EPS
$-3.23
Max Pain — expiry 2026-10-16
max pain strike: $8.00 · spot: $7.64 · call oi: 2,482 · put oi: 429
Expected Move to 2026-10-16:
±$0.68
(8.84%) —
implied range
$6.96 –
$8.31
· ATM straddle on $8.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OCS | Oculis Holding AG | $480.87M | $8.66 | — |
| EPRX | EUPRAXIA PHARMACEUTICALS INC. | $500.18M | $7.57 | — |
| CAPR | CAPRICOR THERAPEUTICS, INC. | $465.69M | $8.01 | — |
| VREOF | Vireo Growth Inc. | $464.97M | $9.15 | — |
| ASMB | ASSEMBLY BIOSCIENCES, INC. | $464.63M | $22.82 | — |
News headlines (Yahoo Finance, 1h cache)
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
2026-10-07 11:00 · Yahoo
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
2026-10-01 20:01 · Yahoo
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-09-29 20:01 · Yahoo
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
2026-09-28 11:00 · Yahoo
Arvinas (ARVN) Just Made Protein Degrader History With FDA Nod
2026-09-09 06:22 · Yahoo
Arvinas to Participate in Upcoming Investor Conferences
2026-09-03 20:01 · Yahoo
Arvinas (ARVN) Q2 2026 Earnings Call Transcript
2026-08-11 18:05 · Yahoo
Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know
2026-08-06 16:00 · Yahoo
Arvinas Q2 Earnings Call Highlights
2026-08-04 14:04 · Yahoo
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-04 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.